Fondazione Policlinico Universitario Agostino Gemelli IRCCS
policlinicogemelli.itTotal trials
888
Active
462
Phase 3
11
Total enrollment
1,135,814
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 80 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Anticoagulant | — | — | — | — | 2 | ||
| Esomeprazole | — | — | — | — | — | 1 | |
| Platinum + Gemcitabine | — | — | — | — | — | 1 | |
| Avelumab first-line maintenance | — | — | — | — | — | 1 | |
| Medical therapy | — | — | — | — | — | 1 | |
| Antiplatelet Drug | — | — | — | — | — | 1 | |
| Statin | — | — | — | — | — | 1 | |
| Beta blocker | — | — | — | — | — | 1 | |
| ACEi/ARB | — | — | — | — | — | 1 | |
| CCB | — | — | — | — | — | 1 | |
| Nitrates | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Standard systemic therapy (chemotherapy) without RT/SBRT | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 2 | ||
| Donor FMT | — | — | — | — | — | 2 | |
| single FMT | — | — | — | — | — | 1 | |
| sequential FMT | — | — | — | — | — | 1 | |
| FMT | — | — | — | — | — | 1 | |
| CAR T cell | — | — | — | — | — | 1 | |
| Bleomicina | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Donor - FMT | — | — | — | — | — | 1 | |
| Organoid-guided treatment | — | — | — | — | — | 1 | |
| encorafenib + cetuximab + FOLFIRI | — | — | — | — | — | 1 | |
| CDK4/6 Inhibitor | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | 5 | |||
| Paclitaxel | — | — | — | 4 | |||
| Pembrolizumab | — | — | — | — | 4 | ||
| Osimertinib | — | — | — | — | 2 | ||
| antibiotic treatments | — | — | — | — | — | 1 | |
| target therapies | — | — | — | — | — | 1 | |
| Placenta organoids treatment | — | — | — | — | — | 1 | |
| AIRE single gene sequencing | — | — | — | — | — | 1 | |
| Molecular typing of HLA class I and II alleles | — | — | — | — | — | 1 | |
| Hospital-Based Vaccination Pathway | — | — | — | — | — | 1 | |
| antithrombotic drugs | — | — | — | — | — | 1 | |
| Diagnostic Test | — | — | — | — | — | 1 | |
| Alectinib | — | — | — | — | — | 1 | |
| Brigatinib | — | — | — | — | — | 1 |
40 more active programs hidden
Next readouts
- 2022-12-31
- 2023-04-01
- 2023-05-01
- 2024-09-29
- 2025-01-31
- 2025-03-31
- 2025-06-15
- 2025-06-30
- 2025-07
- 2025-07-31
Top conditions
- Ovarian Cancer25
- Breast Cancer20
- Gynecologic Cancer13
- Parkinson Disease12
- Obesity12
- COVID-1911
- Endometrial Cancer11
- HIV Infections9
Frequently asked questions about Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- How many clinical trials does Fondazione Policlinico Universitario Agostino Gemelli IRCCS have on ClinicalTrials.gov?
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS is listed as the lead sponsor on 888 clinical trials in ClinicalTrials.gov, 462 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fondazione Policlinico Universitario Agostino Gemelli IRCCS's trials are in Phase 3?
- 11 of Fondazione Policlinico Universitario Agostino Gemelli IRCCS's trials are in Phase 3, spread across 80 active drug programs.
- What therapeutic areas does Fondazione Policlinico Universitario Agostino Gemelli IRCCS focus on?
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS's most-studied conditions on ClinicalTrials.gov are Ovarian Cancer, Breast Cancer, Gynecologic Cancer, Parkinson Disease, Obesity.
- When are Fondazione Policlinico Universitario Agostino Gemelli IRCCS's next clinical trial readouts?
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 10 upcoming primary-completion readouts tracked here; the soonest is “An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity”, expected around 2022-12-31.